Incyte Corporation (BIT:1INCY)

Market Cap	14.39B
Revenue (ttm)	3.90B
Net Income (ttm)	741.55M
Shares Out	n/a
EPS (ttm)	3.72
PE Ratio	19.40
Forward PE	13.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4
Average Volume	3
Open	74.82
Previous Close	72.00
Day's Range	73.02 - 74.82
52-Week Range	47.33 - 77.24
Beta	n/a
RSI	57.37
Earnings Date	Oct 28, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD